Abstract:Background: Furosemide is a commonly used loop diuretic in critical care. However, its effect on the progression of oliguric acute kidney injury across different central venous pressure (CVP) remains unknown. This study therefore aims to investigate the association between furosemide(6-12h ) (defined as the use of furosemide within 6 h after the diagnosis of AKI according to the urine output [UO] criteria set by the Kidney Disease: Improving Global Outcomes [KDIGO] guidelines) and the progression of AKI across different CVP6-12h (defined as CVP within 6 h after the diagnosis of AKI by the KDIGO UO criteria) levels. Methods: Patients involved in this study were identified from the Medical Information Mart for Intensive Care IV database with the following criteria: (i) adults with UO < 0.5 mL/kg per hour for the first 6 h upon admission to the intensive care unit (ICU) (meeting stage 1 AKI by UO) and (ii) CVP6-12h ranging from 0 to 30 mm Hg. From there on, the target primary outcome would be progression to stage 3 AKI by UO among these chosen patients. The secondary outcome was 28-d mortality since ICU admission. The risks of severe-stage AKI progression and 28-d mortality were respectively examined against furosemide(6-12h ) (vs. without furosemide6-12h) within the full cohort and across different subgroups of CV6-12h , using multivariate adjusted logistic regression and inverse probability treatment weighting (IPTW). Sensitivity analyses were performed to assess the robustness of our findings. Results: One thousand one hundred eighty patients were ultimately selected for this study, of whom 643 (54.5%) progressed to stage 3 AKI from stage 1 based on the UO criteria by KDIGO. Multivariate analysis showed that furosemide(6-12h ) is significantly associated with this severe-stage progression within the full cohort (odds ratio [OR] was 0.62 at 95% confidence interval [CI] of 0.43-0.90, P = 0.011). After dividing the patients into CVP6-12h subgroups according to their CVP during the early phases, lower risk of AKI progression was observed only in furosemide(6-12h ) application at CVP6-12h of > 12 mm Hg (adjusted OR was 0.40 at 95% CI of 0.25-0.65, P < 0.001), as confirmed by the IPTW analysis (OR was 0.47 at 95% CI of 0.29-0.76, P = 0.002). The robustness of these findings was confirmed by sensitivity analyses. In addition, for patients with CVP6-12h > 12 mm Hg, furosemide(6-12h ) is also significantly associated with lower risk of 28-d mortality (adjusted OR was 0.47 at 95% CI of 0.25-0.92, P = 0.026) in the multivariate logistic regression analysis, and there was a similar trend in the IPTW analysis (adjusted OR was 0.55 at 95% CI of 0.28-1.10, P = 0.092). Conclusions: Among the identified early-stage AKI patients in critical care, the use of furosemide was associated only with lower risk of oliguric AKI progression and 28-d mortality within the high CVP group. These findings suggest the potential of CVP as a guidance or reference point in the usage of furosemide among early-stage oliguric AKI patients in the ICU.

Association between furosemide administration and clinical outcomes in patients with sepsis-associated acute kidney injury receiving renal replacement therapy: a retrospective observational cohort study based on MIMIC-IV database

Association Between Furosemide Administration and Outcomes in Critically Ill Patients with Acute Kidney Injury.

Association Between Furosemide Exposure and Clinical Outcomes in a Retrospective Cohort of Critically Ill Children.

The effects of early-phase furosemide use on the progression of oliguric acute kidney injury across different central venous pressure: a retrospective analysis

Furosemide responsiveness predicts acute kidney injury progression after cardiac surgery

Furosemide Does Not Reduce the Incidence of Postoperative Acute Kidney Injury in Adult Patients Undergoing Cardiac Surgery: A PRISMA‐compliant Systematic Review and Meta‐analysis

Effects of low-dose furosemide combined with aminophylline on the renal function in septic shock patients

Long-term Renal and Overall Survival of Critically Ill Patients with Acute Renal Injury Who Received Continuous Renal Replacement Therapy.

Effect of the Intensity of Continuous Renal Replacement Therapy in Patients with Sepsis and Acute Kidney Injury: a Single-Center Randomized Clinical Trial

Effect of furosemide combined with continuous renal replacement therapy on cardiorenal function and inflammatory response in patients with chronic renal and heart failure after hemodialysis

Use of furosemide in preterm neonates with acute kidney injury is associated with increased mortality: results from the TINKER registry

Effect of Combining Furosemide With Standard Hydration Therapy on Contrast-Induced Acute Kidney Injury Following Coronary Angiography or Intervention in a High-Risk Population

Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis

Furosemide in pediatric intensive care: a retrospective cohort analysis

Increased 28‐day mortality due to fluid overload prior to continuous renal replacement in sepsis associated acute kidney injury

Effect of Continuous Furosemide Infusion on Outcome of Acute Kidney Injury.

Clinical outcomes of severe sepsis and septic shock patients with left ventricular dysfunction undergoing continuous renal replacement therapy

Timely Renal Replacement Therapy Linked to Better Outcome in Patients with Sepsis-Associated Acute Kidney Injury

The furosemide stress test predicts the timing of continuous renal replacement therapy initiation in critically ill patients with acute kidney injury: a double-blind prospective intervention cohort study

Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation

Diuretic Use in Post-Kidney Transplant Patients: A Retrospective Chart Review